How much can biosimilars actually cut treatment costs?
Biosimilars for retinal diseases like ranibizumab and aflibercept are priced 20–40% lower than the originator drugs, according to pharmacoeconomic analyses [3]. That means a treatment that might cost $1,000 per injection could drop to $600–$800, which adds up over the multiple injections patients typically need each year. In Europe, where biosimilars have been on the market longer, the cumulative savings across all biologic medicines—not just eye drugs—exceeded €30 billion since 2011, showing the scale of potential savings when competition takes hold [1].
In India, a 2020 survey of retina specialists found that the ranibizumab biosimilar was priced at about $130 per dose, and 40% of respondents said that price was low enough to replace Avastin (bevacizumab), the cheaper off-label alternative [2]. This suggests that biosimilars can narrow the cost gap between expensive branded drugs and cheaper alternatives, making treatment more affordable for patients and health systems.
Do biosimilars work as well as the original drugs?
Yes, the evidence shows that approved anti-VEGF biosimilars are therapeutically equivalent to their reference products. A systematic review and meta-analysis of ranibizumab biosimilar (Razumab) across 18 studies with 3,740 eyes found significant improvements in visual acuity and reductions in retinal thickness, with an acceptable safety profile—about 17% of patients had adverse events, mostly non-serious [4]. This matches the efficacy and safety seen with the originator ranibizumab, supporting its use in real-world practice.
Regulatory approvals are based on rigorous standards: the FDA and EMA require comprehensive analytical, preclinical, and clinical data to prove biosimilarity [3]. For example, the FDA granted interchangeability status to CIMERLI/ranibizumab-eqrn without requiring switching studies, citing the totality of evidence that switching between the biosimilar and the reference product poses no greater risk than staying on the reference [5]. This gives clinicians and patients confidence that biosimilars are a safe and effective option.
Why aren't savings universal? The catch is market uptake
Despite the cost advantages, biosimilar uptake varies dramatically by region. In Europe, 92% of surveyed rheumatologists prescribed biosimilars to at least 25% of their patients in 2020, up from 70% in 2018, driving competitive pricing and savings [1]. In contrast, US biosimilars made up only 2.3% of the biologicals marketplace in 2023, largely due to patent litigation and regulatory hurdles that delayed market entry [1]. This means that even when biosimilars are approved, they may not reach patients quickly enough to lower costs.
In India, a 2020 survey showed that while awareness of biosimilars was universal (100% of respondents), the use of ranibizumab biosimilars increased from 41% to 56% between 2018 and 2020, but bevacizumab biosimilar use declined from 9% to 2% [2]. This suggests that even in markets with biosimilars, physicians may be cautious about switching, and preferences can shift based on real-world experience and safety perceptions. The bottom line: biosimilars can lower costs, but realizing those savings requires overcoming legal, regulatory, and physician adoption barriers.
About These Sources
This answer is built on 5 peer-reviewed studies — published from 2021 to 2026, 2 from 2024 or later, 3 in Q1 journals — selected as the most relevant from 8 studies that passed quality screening, drawn from 54 papers retrieved from a database of over 500 million.
Sources used in this answer
Biosimilars and the era of interchangeability
A 2023 Lancet Rheumatology editorial highlights that in Europe, biosimilar competition has saved over €30 billion since 2011, but US biosimilars account for only 2.3% of the biologicals market due to patent and regulatory barriers.
Changing trends in the use of anti-vascular endothelial growth factor (anti-VEGF) biosimilars
A 2020 survey of Indian retina specialists found that ranibizumab biosimilar use increased from 41% to 56% between 2018 and 2020, and 40% considered its $130 price low enough to replace Avastin, though bevacizumab biosimilar use declined.
Biosimilars of anti-VEGF agents in retinal diseases: a narrative review of regulatory, clinical, and pharmacoeconomic aspects.
A narrative review of anti-VEGF biosimilars reports that pharmacoeconomic analyses show 20-40% cost reductions compared to originators, with comparable efficacy and safety, though real-world data for aflibercept biosimilars are still preliminary.
Efficacy and safety of ranibizumab biosimilar for retinal diseases: A systematic review and meta-analysis
A meta-analysis of 18 studies (3,740 eyes) on ranibizumab biosimilar Razumab found significant visual and anatomical improvements with an acceptable safety profile (17.1% adverse events, mostly non-serious), though with heterogeneity and potential publication bias.
Biosimilar ranibizumab interchangeability: what does it mean to retinal physicians?
A 2022 article explains that the FDA granted interchangeability to CIMERLI/ranibizumab-eqrn without switching studies, based on totality of evidence, and that interchangeability allows pharmacy-level substitution without prescriber involvement, though Europe does not use this legal term.